Latest Colorectal cancer Stories

A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this week. (A transcriptome is all RNA produced by a population of cells.) Pr. Pierre Laurent-Puig and colleagues from INSERM in Paris, France used genetic information from a French multicenter study supported by the "Ligue contre le cancer" to identify a standard,...

Studies presented at DDW® 2013 highlight benefits of vitamin D, diet changes, acupuncture Research presented at Digestive Disease Week® (DDW) explores new methods for managing digestive health through diet and lifestyle. Individuals suffering from Crohn's disease are often plagued by reduced muscle strength, fatigue and poor quality of life. These symptoms can remain even when patients are in remission. A randomized, double blind, placebo-controlled study found for the first time that...

Innovation for healthy outcomes presented at DDW® 2013 The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week® (DDW). The preparation process, which begins days in advance of the procedure, includes dietary restrictions and requires specific bowel preparation medication to be taken at strict intervals. The better the preparation, the easier it is for doctors to see cancer and...

Colonoscopy withdrawal time, polyp removal technique also examined at DDW® 2013 A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week® (DDW). Additional research focuses on optimizing the minimal withdrawal time for colonoscopies and exploring safer methods for removing polyps. During colonoscopy, doctors use a device called a colonoscope to examine the colon. This screening test for...

New findings validate clinical utility in Colorectal Cancer Staging MONTREAL, May 16, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"), today announced that results from a large validation study of the Previstage(TM) GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology((R)) (ASCO((R))) Annual Meeting, taking place in Chicago, Illinois from May 31 to June 4, 2013. The results of the...

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix(®) (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive...

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. "The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said Sean E. Harper, M.D., executive vice president...

Spring dedication at Huntsville Botanical Garden displays new gardens symbolizing hope and courage in the fight against cancer HUNTSVILLE, Ala., May 14, 2013 /PRNewswire/ -- One brave woman currently undergoing chemotherapy and two cancer survivors, their families, friends and members of the Huntsville community celebrated life today at the Intergraph(® )Garden of Hope spring dedication in a poignant display of inspiration at the Huntsville Botanical Garden. (Logo:...

Study Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting THOUSAND OAKS, Calif., May 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix(®) (panitumumab) versus Erbitux(®) (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint of non-inferiority for overall survival. The...

Advances in Treatment Have Major Impact on Short- and Long-term Outcomes NORTHBROOK, Ill., May 7, 2013 /PRNewswire-USNewswire/ -- The American College of Chest Physicians (ACCP) third edition of evidence-based lung cancer guidelines, Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, recommends offering low-dose computed tomography (LDCT) scanning for lung cancer screening to people with a significant...